TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
B: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Acetylasalicylic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylasalicylic acid
B: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Apixaban 5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Apixaban 2.5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin sodium | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 5mg BID | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 2.5mg BID | Intervention Type: DRUG; Name: Warfarin sodium; Assigned to Arm(s): Warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
D: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
B: Arm Label: dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care
C: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
D: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
C: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
D: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin

Answer: D